109 related articles for article (PubMed ID: 12914384)
1. Pharmacogenetics of stomach cancer.
Toffoli G; Cecchin E
Suppl Tumori; 2003; 2(5):S19-22. PubMed ID: 12914384
[TBL] [Abstract][Full Text] [Related]
2. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
[TBL] [Abstract][Full Text] [Related]
3. Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.
Ji M; Xu B; Jiang JT; Wu J; Li XD; Zhao WQ; Zhang HY; Zhou WJ; Wu CP
Onkologie; 2013; 36(6):335-40. PubMed ID: 23774147
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Bosch TM; Meijerman I; Beijnen JH; Schellens JH
Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
[TBL] [Abstract][Full Text] [Related]
5. Determinants of chemosensitivity in gastric cancer.
Park DJ; Lenz HJ
Curr Opin Pharmacol; 2006 Aug; 6(4):337-44. PubMed ID: 16777480
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment.
Shimoyama S
J Gastroenterol Hepatol; 2009 Jun; 24(6):970-81. PubMed ID: 19638079
[TBL] [Abstract][Full Text] [Related]
8. Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.
Toffoli G; Cecchin E
J Chemother; 2004 Nov; 16 Suppl 4():31-5. PubMed ID: 15688606
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.
Liu YP; Ling Y; Qi QF; Zhang YP; Zhang CS; Zhu CT; Wang MH; Pan YD
Mol Med Rep; 2013 Jun; 7(6):1904-11. PubMed ID: 23604281
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics in cancer treatment.
Nagasubramanian R; Innocenti F; Ratain MJ
Annu Rev Med; 2003; 54():437-52. PubMed ID: 12525681
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
Bosch TM
Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Huang ZH; Hua D; Du X
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
[TBL] [Abstract][Full Text] [Related]
13. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
[TBL] [Abstract][Full Text] [Related]
14. Update on pharmacogenetics in cancer chemotherapy.
Innocenti F; Ratain MJ
Eur J Cancer; 2002 Mar; 38(5):639-44. PubMed ID: 11916544
[TBL] [Abstract][Full Text] [Related]
15. Multiple Genetic Polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan.
Huang MY; Wang YH; Chen FM; Lee SC; Fang WY; Cheng TL; Hou MF; Wang JY; Lin SR
Ann Surg Oncol; 2008 Mar; 15(3):872-80. PubMed ID: 18095031
[TBL] [Abstract][Full Text] [Related]
16. TFPI-2 downregulates multidrug resistance protein in 5-FU-resistant human hepatocellular carcinoma BEL-7402/5-FU cells.
Lu F; Hou YQ; Song Y; Yuan ZJ
Anat Rec (Hoboken); 2013 Jan; 296(1):56-63. PubMed ID: 23125179
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics and stomach cancer: an update.
Toffoli G; Cecchin E
Pharmacogenomics; 2007 May; 8(5):497-505. PubMed ID: 17465714
[TBL] [Abstract][Full Text] [Related]
18. Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives.
Candelaria M; Taja-Chayeb L; Arce-Salinas C; Vidal-Millan S; Serrano-Olvera A; Dueñas-Gonzalez A
Anticancer Drugs; 2005 Oct; 16(9):923-33. PubMed ID: 16162969
[TBL] [Abstract][Full Text] [Related]
19. [Reversal of multidrug resistance of gastric cancer cells by down-regulation of CIAPIN1 with CIAPIN1 siRNA].
Li X; Fan R; Zou X; Hong L; Gao L; Jin H; Du R; He L; Xia L; Fan D
Mol Biol (Mosk); 2008; 42(1):102-9. PubMed ID: 18389626
[TBL] [Abstract][Full Text] [Related]
20. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.
De Mattia E; Toffoli G
Eur J Cancer; 2009 May; 45(8):1333-51. PubMed ID: 19144510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
